

Supplemental Figure 1. Volcano plot of gene expression x *APOE*-ε4 allele interaction results. Genes with p.fdr<0.1 are colored in green.



Supplemental Figure 2. **(A)** *NRP1* expression associations with working memory performance at the final psychological assessment, stratified by *APOE*-ε4 allele status. Overall interaction: *NRP1 x APOE*-ε4, *β*=-0.28, p.fdr=0.02; *APOE*-ε4 carriers, *β*=-0.17, p=0.03; *APOE*-ε4 non-carriers, *β*=0.128, p=7E-04. **(B)** *NRP1* expression associations with cross-sectional semantic memory, stratified by *APOE*-ε4 allele status. Overall interaction: *NRP1 x APOE*-ε4, *β*=-0.31, p.fdr=0.03; *APOE*-ε4 carriers, *β*=-0.19, p=0.096; *APOE*-ε4 non-carriers, *β*=0.12, p=0.006. **(C)** *NRP1* expression associations with endpoint perceptual orientation scores, stratified by *APOE*-ε4 allele status. Overall interaction: *NRP1 x APOE*-ε4, *β*=-0.28, p.fdr=0.028; *APOE*-ε4 carriers, *β*=-0.11, p=0.19; *APOE*-ε4 non-carriers, *β*=0.17, p=2E-04.



Supplemental Figure 3. Correlation matrix for VEGF family gene expression and cell-type marker expression. *ENO2*, neurons; *OLIG2,* oligodendrocytes*; GFAP,* astrocytes*; CD34,* endothelial cells*; CD38,* microglia. *P<0.05, Pearson's correlation

Supplementary Table 1. *VEGF* associations with *APOE* genotype

Gene	β	SE	P
FLT4	0.10	0.06	0.09
FLT1	0.62	0.38	0.10
NRP1	-0.19	0.13	0.14
KDR	0.05	0.04	0.23
PGF	0.18	0.16	0.26
VEGFC	0.02	0.03	0.50
VEGFD	0.02	0.03	0.57
VEGFA	0.31	1.00	0.75
NRP2	-0.01	0.07	0.86
VEGFB	-0.40	2.67	0.88

Supplementary Table 2. *VEGF* x *APOE* expression on Cognition

	Cross-Sectional				Longitudinal			
Gene	**β**	**SE**	**P**	**p.fdr**	**β**	**SE**	**P**	**p.fdr**
VEGFC	-8.37E-04	4.67E-04	0.07	0.47	-9.40E-05	4.96E-05	0.06	0.54
NRP2	-2.13E-04	1.28E-04	0.10	0.47	-2.03E-05	1.37E-05	0.14	0.54
FLT1	-3.61E-05	2.44E-05	0.14	0.47	-2.59E-06	2.47E-06	0.29	0.67
FLT4	-1.77E-04	2.01E-04	0.38	0.78	-2.04E-05	2.13E-05	0.34	0.67
NRP1	-6.60E-05	8.76E-05	0.45	0.78	-1.31E-05	9.36E-06	0.16	0.54
VEGFB	1.89E-06	2.82E-06	0.50	0.78	1.02E-07	2.97E-07	0.73	0.81
PGF	2.82E-05	4.81E-05	0.56	0.78	2.69E-06	5.21E-06	0.61	0.76
VEGFD	-1.16E-04	2.53E-04	0.65	0.78	-6.48E-06	2.72E-05	0.81	0.81
VEGFA	-6.15E-06	1.61E-05	0.70	0.78	-1.47E-06	1.76E-06	0.40	0.67
KDR	-4.27E-05	2.52E-04	0.87	0.87	-1.62E-05	2.71E-05	0.55	0.76

Supplementary Table 3. *APOE-ε4* stratified *VEGF* expression associations with AD Diagnosis

	Interaction				*APOE*-ε4 Carriers				*APOE*-ε4 Non-Carriers			
Gene	**β**	**SE**	**P**	**p.fdr**	**β**	**SE**	**P**	**p.fdr**	**β**	**SE**	**P**	**p.fdr**
NRP1	0.77	0.27	**3.70E-03**	**0.037**	0.45	0.24	0.06	0.24	-0.31	0.12	**0.01**	**0.03**
NRP2	-1.11	0.44	**0.01**	0.06	-0.86	0.40	**0.03**	0.24	0.19	0.20	0.35	0.58
VEGFA	0.07	0.04	0.08	0.17	0.07	0.04	0.08	0.24	-0.01	0.01	0.65	0.73
PGF	-0.29	0.16	0.08	0.17	-0.07	0.14	0.59	0.85	0.18	0.09	**0.047**	0.16
VEGFB	-0.02	0.01	0.07	0.17	1.76E-03	0.01	0.84	0.86	0.02	0.01	**6.66E-04***	**0.01**
FLT1	0.08	0.09	0.38	0.64	0.14	0.08	0.10	0.24	0.02	0.04	0.52	0.73
FLT4	-0.29	0.45	0.53	0.66	0.07	0.39	0.86	0.86	0.42	0.23	0.07	0.17
VEGFD	-0.55	0.82	0.50	0.66	-0.57	0.72	0.43	0.72	0.20	0.41	0.62	0.73
KDR	-0.21	0.70	0.76	0.85	0.28	0.68	0.68	0.85	0.08	0.33	0.80	0.80
VEGFC	0.10	1.21	0.93	0.93	0.93	1.14	0.41	0.72	0.49	0.47	0.30	0.58

Boldface signifies P≤0.05. *denotes results that were significant after adjusting for all models tested for main outcomes (cognition, diagnosis)

Supplementary Table 4. *VEGF* x *APOE*-ε4 interactions on working memory performance

	Interaction				*APOE*-ε4 Carriers				*APOE*-ε4 Non-Carriers			
Gene	**β**	**SE**	**P**	**p.fdr**	**β**	**SE**	**P**	**p.fdr**	**β**	**SE**	**P**	**p.fdr**
NRP1	-0.29	0.08	**2.46E-04**	**2.46E-03**	-0.17	0.08	**0.03**	0.26	0.13	0.04	**6.87E-04**	**0.01**
VEGFA	-0.03	0.01	**0.02**	0.09	-0.02	0.01	0.05	0.26	0.01	4.73E-03	0.29	0.60
KDR	0.49	0.26	0.06	0.19	0.42	0.27	0.12	0.30	-0.10	0.12	0.42	0.60
VEGFB	0.01	0.00	0.16	0.40	5.93E-04	3.94E-03	0.88	0.93	-4.86E-03	1.80E-03	0.01	0.04
FLT4	-0.16	0.16	0.31	0.53	-0.26	0.16	0.10	0.30	-0.08	0.08	0.36	0.60
FLT1	-0.03	0.03	0.32	0.53	-0.03	0.02	0.21	0.42	-3.49E-03	0.01	0.79	0.79
NRP2	-0.04	0.15	0.81	0.94	0.02	0.15	0.89	0.93	0.06	0.07	0.42	0.60
PGF	-0.01	0.06	0.85	0.94	-0.04	0.06	0.57	0.93	-0.01	0.03	0.72	0.79
VEGFD	0.12	0.30	0.68	0.94	-0.03	0.29	0.93	0.93	-0.16	0.15	0.27	0.60
VEGFC	-0.02	0.38	0.96	0.96	-0.14	0.40	0.73	0.93	-0.06	0.17	0.72	0.79

Boldface signifies P≤0.05.

Supplementary Table 5. *VEGF* x *APOE*-ε4 interactions on semantic memory performance

	Interaction				*APOE*-ε4 Carriers				*APOE*-ε4 Non-Carriers			
Gene	**β**	**SE**	**P**	**p.fdr**	**β**	**SE**	**P**	**p.fdr**	**β**	**SE**	**P**	**p.fdr**
NRP1	-0.31	0.10	**3.35E-03**	**0.03**	-0.19	0.12	0.10	0.24	0.13	0.05	**0.01**	**0.03**
VEGFA	-0.04	0.01	**0.01**	**0.04**	-0.03	0.02	**0.04**	0.21	0.01	0.01	0.37	0.62
KDR	0.74	0.34	0.03	0.09	0.81	0.39	0.04	0.21	0.10	0.15	0.48	0.69
FLT4	-0.37	0.21	0.07	0.19	-0.40	0.22	0.08	0.24	-0.04	0.10	0.73	0.73
VEGFD	0.48	0.37	0.20	0.33	0.36	0.41	0.38	0.64	-0.17	0.18	0.32	0.62
VEGFB	0.01	4.98E-03	0.19	0.33	0.00	0.01	0.97	0.97	-0.01	0.00	0.00	0.03
FLT1	-0.04	0.03	0.25	0.35	-0.04	0.04	0.29	0.58	0.01	0.02	0.73	0.73
NRP2	0.06	0.19	0.76	0.84	0.12	0.21	0.56	0.70	0.08	0.09	0.33	0.62
VEGFC	0.20	0.50	0.69	0.84	0.06	0.58	0.91	0.97	-0.08	0.21	0.71	0.73
PGF	-0.01	0.08	0.92	0.92	-0.07	0.09	0.45	0.65	-0.05	0.04	0.16	0.54

Boldface signifies P≤0.05.

Supplementary Table 6. *VEGF* x *APOE*-ε4 interactions on perceptual orientation

	Interaction				*APOE*-ε4 Carriers				*APOE*-ε4 Non-Carriers			
Gene	**β**	**SE**	**P**	**p.fdr**	**β**	**SE**	**P**	**p.fdr**	**β**	**SE**	**P**	**p.fdr**
NRP1	-0.28	0.09	**2.77E-03**	**0.03**	-0.11	0.08	0.19	0.63	0.17	0.04	**1.58E-04**	**1.58E-03**
NRP2	-0.13	0.16	0.44	0.82	0.07	0.14	0.60	0.96	0.21	0.08	**0.01**	**0.04**
FLT4	-0.24	0.19	0.20	0.82	-0.23	0.16	0.15	0.63	0.01	0.10	0.92	0.96
VEGFD	-0.15	0.33	0.65	0.82	-0.05	0.28	0.87	0.96	0.07	0.17	0.67	0.95
VEGFB	2.70E-03	4.41E-03	0.54	0.82	-3.05E-03	3.89E-03	0.43	0.96	-4.50E-03	2.12E-03	0.03	0.11
VEGFC	-0.22	0.47	0.64	0.82	-0.30	0.42	0.49	0.96	0.01	0.20	0.96	0.96
KDR	0.28	0.30	0.35	0.82	0.43	0.27	0.11	0.63	0.19	0.14	0.17	0.33
FLT1	-0.02	0.03	0.60	0.82	4.73E-03	0.03	0.86	0.96	0.02	0.02	0.11	0.27
VEGFA	-4.01E-03	0.01	0.75	0.83	3.88E-03	0.01	0.72	0.96	0.01	0.01	0.20	0.33
PGF	0.01	0.07	0.87	0.87	6.78E-04	0.06	0.99	0.99	-0.01	0.03	0.76	0.95

Boldface signifies P≤0.05.

Supplementary Table 7. *VEGF* x *APOE*-ε4 interactions on episodic memory and perceptual speed

	Episodic Memory				Perceptual Speed			
Gene	**β**	**SE**	**P**	**p.fdr**	**β**	**SE**	**P**	**p.fdr**
VEGFA	-0.03	0.01	0.03	0.16	-4.31E-03	0.01	0.75	0.90
NRP1	-0.22	0.10	0.03	0.16	-0.15	0.10	0.15	0.74
VEGFB	0.01	4.56E-03	0.08	0.19	0.00	4.32E-03	0.78	0.90
FLT1	-0.06	0.03	0.06	0.19	-0.02	0.03	0.51	0.90
KDR	0.51	0.32	0.11	0.22	0.18	0.31	0.55	0.90
NRP2	0.24	0.18	0.19	0.27	0.02	0.18	0.90	0.90
FLT4	-0.27	0.20	0.18	0.27	-0.11	0.19	0.55	0.90
PGF	0.02	0.07	0.77	0.96	0.01	0.07	0.90	0.90
VEGFD	0.01	0.37	0.98	0.98	0.64	0.35	0.07	0.68
VEGFC	0.01	0.49	0.98	0.98	0.20	0.47	0.68	0.90

Supplementary Table 8. *VEGF* x *APOE*-ε4 interactions on AD-related pathology

Note: Used square root of continuous variables (amyloid, tangles, nft, neuritic plaques)

	Amyloid				Tangles				NFT				Neuritic Plaques			
Gene	**β**	**SE**	**DF**	**P**	**β**	**SE**	**DF**	**P**	**β**	**SE**	**DF**	**P**	**β**	**SE**	**DF**	**P**
FLT1	-0.04	0.03	514	0.17	0.02	0.03	514	0.58	-3.0E-03	0.01	518	0.74	7.3E-04	0.01	518	0.95
KDR	-0.24	0.28	516	0.38	-0.39	0.31	516	0.20	-0.09	0.09	520	0.34	-0.01	0.13	520	0.91
NRP1	0.06	0.09	514	0.53	-0.01	0.10	514	0.90	-0.02	0.03	518	0.57	0.04	0.04	518	0.35
VEGFA	0.01	0.01	514	0.58	-0.01	0.01	514	0.31	-3.3E-03	3.8E-03	518	0.40	4.6E-03	0.01	518	0.39
PGF	0.03	0.07	513	0.66	0.10	0.07	513	0.18	0.01	0.02	517	0.76	0.01	0.03	517	0.81
VEGFB	-2.3E-03	4.1E-03	515	0.58	0.01	4.4E-03	515	0.23	5.3E-04	1.4E-03	519	0.70	6.5E-04	1.8E-03	519	0.72
FLT4	0.07	0.18	513	0.70	0.19	0.19	513	0.32	-0.02	0.06	517	0.79	0.03	0.08	517	0.73
NRP2	-0.05	0.17	515	0.79	-0.19	0.18	515	0.30	-0.10	0.05	519	0.07	-0.08	0.07	519	0.29
VEGFC	-0.13	0.42	514	0.75	-0.37	0.46	514	0.42	-0.17	0.14	518	0.21	-0.01	0.19	518	0.97
VEGFD	0.02	0.33	516	0.96	0.21	0.36	516	0.56	0.08	0.11	520	0.47	3.9E-03	0.15	520	0.98

Supplementary Table 9. *VEGF* x *APOE*-ε4 interactions on nonAD-related pathology

	TDP-43				CAA				Atherosclerosis				Arteriolosclerosis			
Gene	**β**	**SE**	**DF**	**P**	**β**	**SE**	**DF**	**P**	**β**	**SE**	**DF**	**P**	**β**	**SE**	**DF**	**P**
FLT4	0.28	0.15	462	0.059	-0.42	0.31	503	0.17	-0.05	0.30	511	0.87	0.06	0.31	512	0.85
VEGFB	4.7E-03	3.4E-03	465	0.17	4.4E-03	0.01	505	0.54	-7.9E-04	0.01	513	0.91	-4.9E-03	0.01	514	0.49
NRP2	-0.17	0.13	464	0.19	-0.05	0.29	505	0.88	-0.40	0.28	513	0.15	-0.31	0.28	514	0.27
FLT1	0.02	0.02	463	0.32	4.9E-03	0.05	504	0.92	-3.7E-03	0.05	512	0.94	0.03	0.05	513	0.55
NRP1	0.04	0.07	463	0.53	-0.08	0.15	504	0.61	-0.05	0.14	512	0.72	0.01	0.16	513	0.92
PGF	0.03	0.05	462	0.54	0.14	0.11	503	0.21	-0.04	0.11	511	0.68	-0.22	0.11	512	0.05
VEGFA	1.1E-03	0.01	463	0.90	0.03	0.02	504	0.12	-0.01	0.02	512	0.57	0.01	0.02	513	0.48
VEGFC	-0.02	0.32	463	0.95	-0.83	0.73	504	0.25	1.10	0.72	512	0.13	0.91	0.76	513	0.23
VEGFD	0.01	0.27	465	0.96	0.01	0.57	506	0.99	3.6E-03	0.55	514	0.99	0.18	0.59	515	0.76
KDR	-0.01	0.23	465	0.97	-0.07	0.48	506	0.88	0.19	0.46	514	0.68	-0.08	0.50	515	0.87

Supplementary Table 9 cont. *VEGF* x *APOE*-ε4 interactions on nonAD-related pathology

	Hippocampal Sclerosis				Gross infarcts				Microinfarcts			
Gene	**β**	**SE**	**DF**	**P**	**β**	**SE**	**DF**	**P**	**β**	**SE**	**DF**	**P**
FLT1	0.16	0.10	514	0.099	0.07	0.06	519	0.28	0.02	0.06	519	0.69
KDR	1.53	0.94	516	0.101	-0.18	0.71	521	0.80	0.23	0.61	521	0.70
FLT4	0.75	0.61	513	0.22	0.08	0.42	518	0.86	0.29	0.37	518	0.44
PGF	0.15	0.21	513	0.47	0.10	0.16	518	0.52	-0.07	0.14	518	0.62
VEGFC	-0.97	1.47	514	0.51	-0.50	1.00	519	0.62	1.26	0.88	519	0.15
VEGFD	0.65	1.29	516	0.62	-1.29	0.86	521	0.13	-0.38	0.69	521	0.59
NRP2	-0.26	0.60	515	0.66	0.16	0.39	520	0.68	0.21	0.35	520	0.55
VEGFA	-0.02	0.04	514	0.67	3.1E-03	0.03	519	0.91	0.01	0.02	519	0.84
NRP1	-0.09	0.33	514	0.79	0.04	0.22	519	0.85	-0.02	0.20	519	0.91
VEGFB	-1.7E-03	0.01	515	0.90	-0.01	0.01	520	0.59	1.7E-03	0.01	520	0.84

Supplementary Table 10. ***VEGFA and NRP1 isoform*** **x** ***APOE*****-ε4 interactions on cross-sectional global cognition**

Isoform	Protein-coding	β	SE	P.fdr	Isoform	Protein-coding	β	SE	P.fdr
VEGFA-212	No	-1.37	0.37	**0.007**	*NRP1-214*	Yes	1.17	0.61	0.10
VEGFA-211	No	-1.07	0.36	**0.028**	*VEGFA-201*	Yes	-0.55	0.30	0.13
NRP1-202	Yes	-4.42	1.53	**0.028**	*NRP1-210*	Yes	-0.53	0.40	0.29
NRP1-201	Yes	-0.37	0.13	**0.028**	*VEGFA-218*	Yes	-1.86	1.48	0.32
VEGFA-205	Yes	-0.05	0.02	**0.028**	*VEGFA-222*	Yes	-0.27	0.27	0.47
VEGFA-216	No	-0.22	0.08	**0.030**	*NRP1-212*	Yes	0.96	1.24	0.56
VEGFA-207	Yes	-3.32	1.28	**0.033**	*VEGFA-204*	Yes	-0.22	0.29	0.56
NRP1-208	Yes	-9.13	3.55	**0.033**	*VEGFA-209*	Yes	-0.11	0.15	0.56
NRP1-209	Yes	-1.12	0.44	**0.033**	*NRP1-203*	Yes	3.40	4.88	0.57
NRP1-205	Yes	-1.79	0.72	**0.033**	*VEGFA-206*	Yes	0.10	0.16	0.60
VEGFA-214	No	-0.37	0.15	**0.041**	*NRP1-207*	Yes	-0.06	0.11	0.60
VEGFA-215	No	-0.08	0.03	0.053	*VEGFA-225*	Yes	-0.05	0.48	0.95
NRP1-204	Yes	1.90	0.98	0.10	*NRP1-213*	Yes	-0.15	2.80	0.96

Boldface signifies corrected P.fdr≤0.05.

P.fdr column contains p-values corrected for 26 tests using the false discovery rate (FDR).

Supplementary Table 11. Cross-sectional *VEGF* x *APOE*-ε4 interactions on global cognition adjusted for cell-type effects

Note: ENO2 was used as the marker for neurons, CD68 for microglia, OLIG2 for oligodendrocytes, GFAP for astrocytes, and CD34 for endothelial cells.

Part 1: Correction for ENO2 *levels*

	Cross-sectional Results			Cross-sectional Results - ENO2 Covariate			Cross-sectional Results - Adjusted for ENO2		
Gene	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**
NRP1	-0.29	0.08	**0.004**	-0.29	0.08	**0.003**	-0.29	0.08	**0.004**
VEGFA	-0.03	0.01	**0.026**	-0.03	0.01	**0.016**	-0.03	0.01	**0.026**
FLT1	-0.06	0.03	0.12	-0.06	0.03	0.09	-0.07	0.03	**0.041**
FLT4	-0.24	0.16	0.30	-0.25	0.16	0.32	-0.43	0.20	0.07
VEGFB	0.01	0.004	0.30	0.01	0.00	0.34	0.01	0.01	0.23
KDR	0.29	0.26	0.43	0.29	0.25	0.42	0.31	0.28	0.46
VEGFD	0.24	0.31	0.62	0.28	0.30	0.51	0.23	0.30	0.57
PGF	-0.02	0.06	0.81	-0.03	0.06	0.75	-0.07	0.08	0.48
VEGFC	-0.14	0.39	0.81	-0.13	0.39	0.75	-0.21	0.42	0.68
NRP2	0.02	0.15	0.88	0.05	0.15	0.75	0.02	0.16	0.91

Boldface signifies corrected P.fdr≤0.05.

P.fdr column contains p-values corrected for 10 tests using the false discovery rate (FDR).

Part 2: Adjusting for expression of other cell-type markers

	Cross-sectional Results			Cross-sectional Results - OLIG2, GFAP, CD68, and CD34 Covariates			Cross-sectional Results - Adjusted for OLIG2			Cross-sectional Results - Adjusted for GFAP			Cross-sectional Results - Adjusted for CD68			Cross-sectional Results - Adjusted for CD34		
Gene	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**
NRP1	-0.29	0.08	**0.004**	-0.30	0.08	**0.003**	-0.29	0.08	**0.004**	-0.30	0.09	**0.005**	-0.25	0.08	**0.028**	-0.29	0.08	**0.003**
VEGFA	-0.03	0.01	**0.026**	-0.03	0.01	**0.031**	-0.03	0.01	**0.027**	-0.02	0.01	0.13	-0.02	0.01	0.14	-0.03	0.01	**0.011**
FLT1	-0.06	0.03	0.12	-0.07	0.03	0.057	-0.08	0.03	**0.036**	-0.04	0.03	0.31	-0.04	0.03	0.30	-0.06	0.03	0.18
FLT4	-0.24	0.16	0.30	-0.22	0.17	0.43	-0.29	0.18	0.24	-0.14	0.17	0.68	-0.13	0.17	0.63	-0.27	0.19	0.28
VEGFB	0.01	0.004	0.30	0.01	0.00	0.43	0.01	0.00	0.24	0.01	0.00	0.31	0.01	0.00	0.30	0.01	0.00	0.22
KDR	0.29	0.26	0.43	0.19	0.27	0.73	0.34	0.28	0.39	0.39	0.26	0.31	0.32	0.26	0.44	0.45	0.29	0.23
VEGFD	0.24	0.31	0.62	0.15	0.31	0.79	0.25	0.30	0.60	0.22	0.31	0.68	0.18	0.31	0.70	0.22	0.31	0.68
PGF	-0.02	0.06	0.81	-0.04	0.07	0.73	-0.04	0.07	0.66	0.01	0.06	0.82	0.00	0.06	1.00	-0.02	0.07	0.84
VEGFC	-0.14	0.39	0.81	-0.13	0.42	0.85	-0.13	0.40	0.83	0.24	0.41	0.69	0.08	0.41	0.93	0.10	0.43	0.84
NRP2	0.02	0.15	0.88	0.01	0.16	0.97	0.02	0.15	0.87	0.04	0.16	0.82	0.15	0.16	0.58	0.03	0.15	0.84

Supplementary Table 12. Longitudinal *VEGF* x *APOE*-ε4 interactions on global cognition adjusted for cell-type effects

Note: ENO2 was used as the marker for neurons, CD68 for microglia, OLIG2 for oligodendrocytes, GFAP for astrocytes, and CD34 for endothelial cells.

Part 1: Adjusting for ENO2 expression

	Longitudinal Results			Longitudinal Results - *ENO2 Covariate*			Longitudinal Results - Adjusted for *ENO2*		
Gene	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**
NRP1	-0.02	0.01	0.44	-0.02	0.01	0.46	-0.01	0.01	0.57
KDR	0.04	0.03	0.44	0.04	0.03	0.46	0.04	0.03	0.57
VEGFB	0.001	4.16E-04	0.44	5.9E-04	4.2E-04	0.46	4.0E-04	6.1E-04	0.64
VEGFA	-0.002	0.001	0.44	-1.6E-03	1.2E-03	0.46	-1.5E-03	1.2E-03	0.57
VEGFD	0.04	0.03	0.57	0.04	0.03	0.56	0.03	0.03	0.57
NRP2	0.01	0.02	0.82	0.01	0.02	0.83	0.01	0.02	0.73
VEGFC	0.02	0.04	0.87	0.02	0.04	0.86	1.1E-03	0.05	0.98
FLT4	-0.01	0.02	0.90	-0.01	0.02	0.90	-0.03	0.02	0.57
FLT1	-4.65E-04	0.003	0.92	-4.3E-04	2.9E-03	0.93	-2.1E-03	3.2E-03	0.64
PGF	0.001	0.01	0.92	6.1E-04	0.01	0.93	-0.01	0.01	0.57

Part 2: Adjusting for expression of other cell-type markers

	Longitudinal Results			**Longitudinal Results - *OLIG2, GFAP, CD68, and CD34 Covariates***			**Longitudinal Results - Adjusted for *OLIG2***			**Longitudinal Results - Adjusted for *GFAP***		
Gene	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**
NRP1	-0.02	0.01	0.44	-0.02	0.01	0.64	-0.01	0.01	0.49	-0.02	0.01	0.53
KDR	0.04	0.03	0.44	0.04	0.03	0.64	0.05	0.03	0.49	0.05	0.03	0.53
VEGFB	0.001	4.16E-04	0.44	5.7E-04	4.4E-04	0.64	7.3E-04	5.2E-04	0.49	5.6E-04	4.2E-04	0.53
VEGFA	-0.002	0.001	0.44	-1.3E-03	1.2E-03	0.64	-1.5E-03	1.2E-03	0.49	-1.2E-03	1.2E-03	0.53
VEGFD	0.04	0.03	0.57	0.03	0.03	0.64	0.04	0.03	0.56	0.04	0.03	0.53
NRP2	0.01	0.02	0.82	0.01	0.02	0.73	0.01	0.02	0.71	0.01	0.02	0.62
VEGFC	0.02	0.04	0.87	0.03	0.05	0.73	0.02	0.05	0.71	0.05	0.05	0.53
FLT4	-0.01	0.02	0.90	-1.4E-03	0.02	0.94	-0.01	0.02	0.71	-1.3E-03	0.02	0.95
FLT1	-4.65E-04	0.003	0.92	-8.3E-04	3.2E-03	0.94	-1.8E-03	3.3E-03	0.71	7.8E-04	3.0E-03	0.88
PGF	0.001	0.01	0.92	-6.4E-04	0.01	0.94	-2.1E-03	0.01	0.79	2.8E-03	0.01	0.87

Part 3: Adjusting for expression of other cell-type markers

	Longitudinal Results			Longitudinal Results - Adjusted for *CD68*			Longitudinal Results - Adjusted for *CD34*		
Gene	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**	**β**	**SE**	**P.fdr**
NRP1	-0.02	0.01	0.44	-0.01	0.01	0.49	-0.01	0.01	0.37
KDR	0.04	0.03	0.44	0.04	0.03	0.49	0.05	0.03	0.37
VEGFB	0.001	4.16E-04	0.44	6.2E-04	4.2E-04	0.49	6.7E-04	4.4E-04	0.37
VEGFA	-0.002	0.001	0.44	-1.2E-03	1.2E-03	0.51	-1.7E-03	1.2E-03	0.37
VEGFD	0.04	0.03	0.57	0.04	0.03	0.51	0.03	0.03	0.62
NRP2	0.01	0.02	0.82	0.02	0.02	0.49	0.01	0.02	0.71
VEGFC	0.02	0.04	0.87	0.04	0.05	0.54	0.04	0.05	0.64
FLT4	-0.01	0.02	0.90	-6.3E-04	0.02	0.98	-0.01	0.02	0.94
FLT1	-4.65E-04	0.003	0.92	6.9E-05	3.0E-03	0.98	-2.6E-04	3.3E-03	0.94
PGF	0.001	0.01	0.92	2.2E-03	0.01	0.94	6.0E-04	0.01	0.94